Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 16.75
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell